BRPI0909100A2 - Composição de cetorolaco de trometamina para tratar ou prevenir dor ocular - Google Patents

Composição de cetorolaco de trometamina para tratar ou prevenir dor ocular

Info

Publication number
BRPI0909100A2
BRPI0909100A2 BRPI0909100-9A BRPI0909100A BRPI0909100A2 BR PI0909100 A2 BRPI0909100 A2 BR PI0909100A2 BR PI0909100 A BRPI0909100 A BR PI0909100A BR PI0909100 A2 BRPI0909100 A2 BR PI0909100A2
Authority
BR
Brazil
Prior art keywords
treating
eye pain
preventing eye
tromethamine
ketorolac composition
Prior art date
Application number
BRPI0909100-9A
Other languages
English (en)
Inventor
Eldon Quinn Farnes
Mayssa Attar
Rhett M Schiffman
Chin-Ming Chang
Richard S Graham
Devin F Welty
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40852460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909100(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0909100A2 publication Critical patent/BRPI0909100A2/pt
Publication of BRPI0909100B1 publication Critical patent/BRPI0909100B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0909100A 2008-03-03 2009-03-03 composições de cetorolaco de trometamina para tratar ou prevenir dor ocular BRPI0909100B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6792508P 2008-03-03 2008-03-03
US9609608P 2008-09-11 2008-09-11
US11191908P 2008-11-06 2008-11-06
US12/396,131 US7842714B2 (en) 2008-03-03 2009-03-02 Ketorolac tromethamine compositions for treating ocular pain
PCT/US2009/035787 WO2009111418A2 (en) 2008-03-03 2009-03-03 Ketorolac tromethamine compositions for treating or preventing ocular pain

Publications (2)

Publication Number Publication Date
BRPI0909100A2 true BRPI0909100A2 (pt) 2015-08-11
BRPI0909100B1 BRPI0909100B1 (pt) 2019-01-15

Family

ID=40852460

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909100A BRPI0909100B1 (pt) 2008-03-03 2009-03-03 composições de cetorolaco de trometamina para tratar ou prevenir dor ocular

Country Status (20)

Country Link
US (10) US7842714B2 (pt)
EP (2) EP2257275B1 (pt)
JP (1) JP5705552B2 (pt)
KR (1) KR101560429B1 (pt)
CN (1) CN102014869A (pt)
AT (1) ATE538775T1 (pt)
AU (1) AU2009222016B2 (pt)
BR (1) BRPI0909100B1 (pt)
CA (1) CA2717520C (pt)
CO (1) CO6321226A2 (pt)
DK (2) DK2446878T3 (pt)
ES (2) ES2382509T3 (pt)
HU (1) HUE027102T2 (pt)
IL (1) IL207925A (pt)
MX (1) MX2010009763A (pt)
MY (1) MY150250A (pt)
NZ (2) NZ588367A (pt)
PL (2) PL2446878T3 (pt)
WO (1) WO2009111418A2 (pt)
ZA (1) ZA201006372B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004023516D1 (de) * 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
SI2555770T1 (en) * 2010-04-09 2018-04-30 Allergan, Inc. Ketorolac compositions for corneal wound healing
BR112014012885A2 (pt) * 2011-12-06 2017-06-13 Alcon Res Ltd composição de gel celulósica com estabilidade de viscosidade aperfeiçoada
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
DE102013006596A1 (de) * 2013-04-17 2014-10-23 Jaime Guardiola Verfahren zum Herstellen einer sterilen intraokularen Spül-Lösung und Spül-Lösung
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150335704A1 (en) 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
AU2017310520A1 (en) 2016-08-12 2019-03-21 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
MX2021004708A (es) 2018-10-26 2021-11-03 Ocuphire Pharma Inc Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
WO2020113075A1 (en) * 2018-11-29 2020-06-04 Cellula Llc The composition of umbilical cord blood serum
WO2021141672A2 (en) 2019-11-15 2021-07-15 Silk Technologies, Ltd. Stable formulations of silk-derived protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
DE1544943A1 (de) * 1964-02-12 1969-07-31 Goodrich Co B F Waermehaertbare Vinylplastisole
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4021416A (en) * 1975-05-05 1977-05-03 Polaroid Corporation Thiol polymers
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US6255299B1 (en) 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4861514A (en) 1988-06-08 1989-08-29 The Drackett Company Compositions containing chlorine dioxide and their preparation
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
EP0481007B1 (en) * 1989-06-07 1997-01-22 BAZZANO, Gail S SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids
US5045121A (en) * 1989-06-21 1991-09-03 Gte Products Corporation Method for removing carbon from cemented tungsten carbide articles
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU666957B2 (en) 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US5648074A (en) 1993-05-25 1997-07-15 Allergan Compositions and methods for disinfecting contact lenses and reducing proteinaceous deposit formation
JP3683908B2 (ja) 1993-10-13 2005-08-17 アラーガン、インコーポレイテッド （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5807541A (en) * 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
EP1162984A2 (en) 1999-03-15 2001-12-19 Trustees Of Boston University Use of cross linked polysaccharides for the inhibition of angiogenesis
JP2002541682A (ja) * 1999-04-08 2002-12-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ パンチスルーダイオード及び同ダイオードを製造する方法
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
US7141607B1 (en) * 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
JP4927298B2 (ja) * 2000-07-14 2012-05-09 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
US20020198210A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US8008338B2 (en) * 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
DE602004023516D1 (de) * 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
WO2005101982A2 (en) 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition
ZA200704869B (en) * 2004-12-23 2009-02-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20070299124A1 (en) * 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20090010850A1 (en) 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
US20080039398A1 (en) 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070287741A1 (en) 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
WO2009132088A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss

Also Published As

Publication number Publication date
WO2009111418A2 (en) 2009-09-11
EP2446878A1 (en) 2012-05-02
US20120196913A1 (en) 2012-08-02
NZ588367A (en) 2013-03-28
AU2009222016A1 (en) 2009-09-11
DK2446878T3 (en) 2016-04-04
WO2009111418A3 (en) 2010-04-01
US20230181497A1 (en) 2023-06-15
EP2446878B1 (en) 2015-12-30
CA2717520A1 (en) 2009-09-11
MX2010009763A (es) 2010-12-07
CO6321226A2 (es) 2011-09-20
ZA201006372B (en) 2011-05-25
ATE538775T1 (de) 2012-01-15
ES2382509T3 (es) 2012-06-08
US20250281432A1 (en) 2025-09-11
JP5705552B2 (ja) 2015-04-22
US20120196914A1 (en) 2012-08-02
ES2566162T3 (es) 2016-04-11
US20200197336A1 (en) 2020-06-25
HK1149212A1 (en) 2011-09-30
BRPI0909100B1 (pt) 2019-01-15
PL2446878T3 (pl) 2016-06-30
US7842714B2 (en) 2010-11-30
US20110275688A1 (en) 2011-11-10
DK2257275T3 (da) 2012-04-02
IL207925A (en) 2015-03-31
CA2717520C (en) 2012-05-01
KR20100130989A (ko) 2010-12-14
US20090326034A1 (en) 2009-12-31
EP2257275A2 (en) 2010-12-08
IL207925A0 (en) 2010-12-30
US20110160271A1 (en) 2011-06-30
PL2257275T3 (pl) 2012-05-31
US20110046198A1 (en) 2011-02-24
CN102014869A (zh) 2011-04-13
EP2257275B1 (en) 2011-12-28
MY150250A (en) 2013-12-31
NZ602445A (en) 2014-06-27
KR101560429B1 (ko) 2015-10-15
HUE027102T2 (en) 2016-08-29
US20240197657A1 (en) 2024-06-20
AU2009222016B2 (en) 2014-09-04
JP2011513416A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
IL207925A0 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
BRPI0710085B8 (pt) composições oftálmicas e seus kits
EP2424360A4 (en) TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
BR112013025493A2 (pt) composição aquosa administrável de maneira tópica a um olho humano ou animal, método para tratar uma afecção que envolve deficiências em lágrimas naturais no olho humano ou animal, composição para aplicação tópica no tratamento de um distúrbio ou afecção ocular do olho humano ou animal, método para tratar um distúrbio ou afecção ocular do olho humano ou animal, composição para uso no tratamento de dor associada ao olho humano ou animal e método para alívio da dor no olho humano ou animal ou próximo ao mesmo
BR112012010261A2 (pt) dispositivo de microcânula, e, métodos para tratar o espaço supracoroidal de um olho, para tratar a região posterior de um olho e para tratar os tecidos dentro ou adjacentes ao espaço supracoroidal de um olho
GB0918546D0 (en) Compounds for treating ophthalmic diseases and disorders
HK1198631A1 (en) Prevention and treatment of ocular conditions
BRPI0520014A2 (pt) emulsões oftálmicas estáveis de óleo-em-água com hialuronato de sódio para alìvio de olho seco
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BRPI1016257A2 (pt) composições compreendendo finafloxacino e métodos para tratar infecções oftálmicas, ópticas ou nasais
BRPI0819105A2 (pt) composição para o tratamento e prevenção de edema de pálpebra
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
HK1198811A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
BRPI0923567A2 (pt) agentes antibactericidas novos para o tratamento de infecções gram positivas
NZ704178A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2011097522A3 (en) Combination methods for treatment of disease
EP2251009A4 (en) PROPHYLACTIC OR THERAPEUTIC FOR EYE DISEASE WITH ACCOMPANYING TELEPHONE DISEASE
BR112013013636A2 (pt) processos para o tratamento de doenças da retina
PT2236608T (pt) Péptidos novos para tratar e prevenir distúrbios relacionados com a imunidade, incluindo tratar e prevenir infecção por modulação da imunidade inata
BRPI0815599A2 (pt) Uso de uma fluoroquinolona, métodos para modular endoftalmite em um indivíduo e para tratar ou controlar uma infecção ocular ouo oftálmica que resulta em endoftalmite em um indivíduo, e, composição farmacêutica.
HN2007000505A (es) Analogos de pirazol
BR112015017381A2 (pt) agentes analgésicos oculares tópicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/03/2009, OBSERVADAS AS CONDICOES LEGAIS.